We have located links that may give you full text access.
Journal Article
Randomized Controlled Trial
A randomized comparison of vaginal misoprostol and dinoprostone for cervical priming in nulliparous women before operative hysteroscopy.
Fertility and Sterility 2006 October
OBJECTIVE: To compare the efficacy and side effects of vaginal misoprostol with dinoprostone for cervical priming before operative hysteroscopy and to assess the cervicouterine complications related to cervical dilatation and hysteroscopic surgery.
DESIGN: A prospective randomized study.
SETTING: Tertiary university hospital.
PATIENT(S): Three hundred ten nulliparous women with definite intrauterine lesions.
INTERVENTION(S): Hysteroscopic surgery of intrauterine lesions.
MAIN OUTCOME MEASURE(S): Cervical response, outcome, complications of hysteroscopic surgery, and side effects of both drugs.
RESULT(S): Among the 310 patients recruited, 152 were randomized to the vaginal misoprostol group and 158 to the dinoprostone group. Mean cervical dilatation, cervical dilatation rate, and mean time for cervical dilatation to Hegar 9 were significantly different between the misoprostol group (7.4 +/- 0.8 mm, 70.4%, and 39.5 +/- 18.8 seconds, respectively) and the dinoprostone group (7.0 +/- 0.9 mm, 80.4%, and 43.6 +/- 17.1 seconds, respectively). Cervical tearing during hysteroscopic surgery occurred in 3 patients (2.0%) in the misoprostol group and in 12 patients (7.6%) in the dinoprostone group. There were more side effects in the misoprostol group. The significant difference of side effects between the two groups were abdominal pain, vaginal bleeding, and feeling feverish, which occurred in 36.2%, 29.6%, and 7.2% in the misoprostol group compared to 21.5%, 16.5%, and 1.3%, respectively, in the dinoprostone group.
CONCLUSION(S): Vaginal misoprostol is more effective than dinoprostone for cervical priming in nulliparous women before hysteroscopic surgery. Although more side effects occurred in the misoprostol-treated patients, they were mild. We suggest using vagina misoprostol for cervical priming instead of dinoprostone.
DESIGN: A prospective randomized study.
SETTING: Tertiary university hospital.
PATIENT(S): Three hundred ten nulliparous women with definite intrauterine lesions.
INTERVENTION(S): Hysteroscopic surgery of intrauterine lesions.
MAIN OUTCOME MEASURE(S): Cervical response, outcome, complications of hysteroscopic surgery, and side effects of both drugs.
RESULT(S): Among the 310 patients recruited, 152 were randomized to the vaginal misoprostol group and 158 to the dinoprostone group. Mean cervical dilatation, cervical dilatation rate, and mean time for cervical dilatation to Hegar 9 were significantly different between the misoprostol group (7.4 +/- 0.8 mm, 70.4%, and 39.5 +/- 18.8 seconds, respectively) and the dinoprostone group (7.0 +/- 0.9 mm, 80.4%, and 43.6 +/- 17.1 seconds, respectively). Cervical tearing during hysteroscopic surgery occurred in 3 patients (2.0%) in the misoprostol group and in 12 patients (7.6%) in the dinoprostone group. There were more side effects in the misoprostol group. The significant difference of side effects between the two groups were abdominal pain, vaginal bleeding, and feeling feverish, which occurred in 36.2%, 29.6%, and 7.2% in the misoprostol group compared to 21.5%, 16.5%, and 1.3%, respectively, in the dinoprostone group.
CONCLUSION(S): Vaginal misoprostol is more effective than dinoprostone for cervical priming in nulliparous women before hysteroscopic surgery. Although more side effects occurred in the misoprostol-treated patients, they were mild. We suggest using vagina misoprostol for cervical priming instead of dinoprostone.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app